Literature DB >> 20819048

Changes in serial laboratory test results in snakebite patients: when can we safely exclude envenoming?

Graham Ireland1, Simon G A Brown, Nicholas A Buckley, Jeff Stormer, Bart J Currie, Julian White, David Spain, Geoffrey K Isbister.   

Abstract

OBJECTIVES: To determine which laboratory tests are first associated with severe envenoming after a snakebite, when (ie, how long after the bite) the test results become abnormal, and whether this can determine a safe observation period after suspected snakebite. DESIGN, PATIENTS AND
SETTING: Prospective cohort study of 478 patients with suspected or confirmed snakebite recruited to the Australian Snakebite Project from January 2002 to April 2009, who had at least three sets of laboratory test results and at least 12 hours of observation in hospital after the bite. Severe envenoming was defined as venom-induced consumption coagulopathy (VICC), myotoxicity, neurotoxicity or thrombotic microangiopathy. MAIN OUTCOME MEASURES: International normalised ratio (INR), activated partial thromboplastin time (aPTT), creatine kinase (CK) level, and neurological examination.
RESULTS: There were 240 patients with severe envenoming, 75 with minor envenoming and 163 non-envenomed patients. Of 206 patients with VICC, 178 had an INR > 1.2 (abnormal) on admission, and the remaining 28 had an INR > 1.2 within 12 hours of the bite. Of 33 patients with myotoxicity, a combination of CK > 250 U/L and an abnormal aPTT identified all but two cases by 12 hours; one of these two was identified within 12 hours by leukocytosis. Nine cases of isolated neurotoxicity had a median time of onset after the bite of 4 hours (range, 35 min - 12 h). The combination of serial INR, aPTT and CK tests and repeated neurological examination identified 213 of 222 severe envenoming cases (96%) by 6 hours and 238 of 240 (99%) by 12 hours.
CONCLUSION: Laboratory parameters (INR, aPTT and CK) and neurological reassessments identified nearly all severe envenoming cases within 12 hours of the bite, even in this conservative analysis that assumed normal test results if the test was not done.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20819048     DOI: 10.5694/j.1326-5377.2010.tb03909.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  5 in total

1.  Death adder envenoming causes neurotoxicity not reversed by antivenom--Australian Snakebite Project (ASP-16).

Authors:  Christopher I Johnston; Margaret A O'Leary; Simon G A Brown; Bart J Currie; Lambros Halkidis; Richard Whitaker; Benjamin Close; Geoffrey K Isbister
Journal:  PLoS Negl Trop Dis       Date:  2012-09-27

2.  D-dimer testing for early detection of venom-induced consumption coagulopathy after snakebite in Australia (ASP-29).

Authors:  Geoffrey K Isbister; Tina Noutsos; Shane Jenkins; Katherine Z Isoardi; Jessamine Soderstrom; Nicholas A Buckley
Journal:  Med J Aust       Date:  2022-06-07       Impact factor: 12.776

Review 3.  Snakebite management in Iran: Devising a protocol.

Authors:  Seyed Mostafa Monzavi; Bita Dadpour; Reza Afshari
Journal:  J Res Med Sci       Date:  2014-02       Impact factor: 1.852

4.  Diagnosis of snake envenomation using a simple phospholipase A2 assay.

Authors:  Kalana Maduwage; Margaret A O'Leary; Geoffrey K Isbister
Journal:  Sci Rep       Date:  2014-04-29       Impact factor: 4.379

Review 5.  Snakebite Associated Thrombotic Microangiopathy and Recommendations for Clinical Practice.

Authors:  Tina Noutsos; Bart J Currie; Eranga S Wijewickrama; Geoffrey K Isbister
Journal:  Toxins (Basel)       Date:  2022-01-14       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.